Summary
The randomized Phase 3 Cetuximab Combined With Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer trial [CRYSTAL; Van Cutsem E et al. N Engl J Med 2009] investigated the efficacy and safety of cetuximab combined with a simplified regimen of leucovorin–5-flourouracil—irinotecan (FOLFIRI) for the initial treatment of metastatic colorectal cancer.
- Oncology Clinical Trials
- Gastrointestinal Cancers
- Oncology Clinical Trials
- Gastrointestinal Cancers
- © 2014 MD Conference Express®
Tools
New Analysis of CRYSTAL Results Supports Patient Selection According to RAS Mutation Status to Maximize Benefit from CET Therapy
Permalink:
Table of contents
Cited By...
- No citing articles found.